Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Fibromyalgia (FM) is a disorder characterised by soft tissue pain, disturbance of function an often prolonged course and variable fatigue and debility. A clearly defined aetiology has not been described. This paper proposes that immunological aberration is likely and this may prove to be associated with an expanding group of novel vasoactive neuropeptides. Vasoactive neuropeptides act as hormones, neurotransmitters, immune modulators and neurotrophes. They are readily catalysed to small peptide fragments. They and their binding sites are immunogenic and are known to be associated with a range of autoimmune conditions. They have a vital role in maintaining vascular flow in organs, and in thermoregulation, memory and concentration. They are co-transmitters for acetylcholine, are potent immune regulators with primarily anti-inflammatory activity, and have a significant role in protection of the nervous system to toxic assault and the maintenance of homeostasis.

https://pubmed.ncbi.nlm.nih.gov/15082086/

Fibromyalgia Treatment Market size was valued at USD 2961 Million in 2020 and is projected to reach USD 3876 Million by 2028, growing at a CAGR of 3.45. % from 2021 to 2028. The Global Fibromyalgia Treatment Market is expected to grow at a very fast pace over the projection period.

https://www.verifiedmarketresearch.com/product/fibromyalgia-treatment-market/